Preparation and optimization of monodisperse polymeric microparticles using modified vibrating orifice aerosol generator for controlled delivery of letrozole in breast cancer therapy

Production of letrozole-loaded alginate oxide-gelatin microgels using microfluidic systems for drug delivery applications

Microfluidic systems are capable of producing microgels with a monodisperse size distribution and a spherical shape due to their laminar flow and superior flow. A significant challenge in producing these drug-carrying microgels is simultaneous drug loading into microgels. Various factors such as the type of polymer, the type of drug, the volume ratio of the drug to the polymer, and the geometry of the microfluidic system used to generate microgels can effectively address these challenges. The overall goal of this study was to produce mono-disperse drug-carrying microgels capable of controlled drug release. To achieve this goal, this study used a stream-focused microfluidic chip containing a coating current to prevent chip clogging. Alginate oxide was synthesized with a 30 % oxidation percentage. Alginate oxide, gelatin, and compositions of them with volume ratios of 50-50, 70-30, and 30-70, by determining their appropriate weight percentage, were used for the controlled release of letrozole. The properties of the produced microgels were measured through various tests such as drug release test, loading percentage, SEM, FTIR, swelling ratio, and dimensional stability. It was found that microgels made of a combination of alginate oxide-gelatin with volume ratios of 70-30 had a good swelling ratio and structural stability. The drug loading percentages for alginate, alginate oxide, and alginate oxide-gelatin with volume ratios of 50-50 and 30-70, respectively, were 56 %, 68 %, and 66 %, 61 % and the alginate oxide-gelatin with a volume ratio of 70-30 compared to other samples had over 70 % drug loading percentages. Furthermore, samples of alginate, alginate oxide, and alginate oxide-gelatin with volume ratios of 50-50 and 30-70 had 94 %, 63 %, 56 %, and 68 % drug release in 13 days, respectively. However, alginate oxide-gelatin with a volume ratio of 70-30 had a release rate of about 50 % in 13 days, which is a more controlled release for letrozole compared to the volume ratios of 50-50 and 30-70. Examining the drug release profile, it was concluded that drug release follows the Higuchi model and therefore follows Fick's first law of diffusion. It can be concluded that the combination of alginate oxide-gelatin produces more suitable microgels than alginate and alginate oxide for the controlled-release of letrozole. A comparison of microgels of alginate oxide and gelatin with volume ratios of 50-50 and 70-30 had better results for the cytotoxicity study compared to other samples.

Monodisperse Fluorescent Polystyrene Microspheres for Staphylococcus aureus Aerosol Simulation

Staphylococcus aureus (SA) is one of the most common causes of hospital-acquired infections and foodborne illnesses and is commonly found in nature in air, dust, and water. The spread and transmission of SA aerosols in the air has the potential to cause epidemic transmission among humans and between humans and animals. To effectively provide the timely warning of SA aerosols in the atmosphere, the identification and detection of SA aerosol concentrations are required. Due to their homogeneous physicochemical properties, highly monodisperse submicron polystyrene (PS) microspheres can be used as one of the simulants of SA aerosols. In this study, 800 nm monodisperse fluorescent PS (f-PS) microspheres with fluorescence spectra and particle size distribution similar to those of SA were prepared. The 800 nm monodisperse f-PS microspheres had a fluorescence characteristic peak at 465 nm; in aerosols, 800 nm monodisperse f-PS microspheres with a similar particle size distribution to that of SA were further verified, mainly in the range of 500 nm-1000 nm; finally, it was found that the f-PS microspheres still possessed similar fluorescence characteristics after 180 days. The f-PS microspheres prepared in this study are very close to SA in terms of particle size and fluorescence properties, providing a new idea for aerosol analogs of SA.

A review of FDA approved drugs and their formulations for the treatment of breast cancer

Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.

Redox-Responsive Coordination Polymers of Dopamine-Modified Hyaluronic Acid with Copper and 6-Mercaptopurine for Targeted Drug Delivery and Improvement of Anticancer Activity against Cancer Cells

Dopamine-modified hyaluronic acid (HA-DOP) was chosen as the drug carrier in this study, and Cu²⁺ was selected from among Cu²⁺, Zn²⁺, Fe²⁺, and Ca²⁺ as the central atom. 6-Mercaptopurine (6-MP) was conjugated with HA through a coordination reaction. HA-DOP-copper-MP (HA-DOP-Cu-MP), a redox-responsive coordination polymer prodrug, was prepared. The drug loading was 49.5 mg/g, the encapsulation efficiency was 70.18%, and the particle size was 173.5 nm. HA-DOP-Cu-MP released rapidly in the release medium containing reduced glutathione (GSH), and the accumulated release exceeded 94% in 2 h. In the release medium without GSH, the drug release rate was slow, with only 15% of the 6-MP released in 24 h. Cell uptake experiments revealed the CD44 targeting of HA. Cell viability assays showed that the cytotoxicity of HA-DOP-Cu-MP was higher than that of free 6-MP. Indeed, HA-DOP-Cu-MP is very toxic to cancer cells. In this paper, the redox-responsive drug delivery system was synthesized by a coordination reaction. The tumour targeting and tumour cytotoxicity of 6-MP were improved.